EndomTest
Endometriosis
Commercial (LDT)Active
Key Facts
About Kephera Diagnostics
Kephera Diagnostics is a commercial-stage, private diagnostics company targeting significant unmet needs in infectious diseases and women's health. Its core strategy involves developing novel immunoassays, including point-of-care and ELISA formats, and offering them through its own certified clinical laboratory. The company has launched several first-to-market tests, including a blood-based diagnostic for endometriosis (EndomTest™) and comprehensive panels for parasitic infections like Chagas disease and liver fluke, supported in part by NIH grants. Kephera's model combines proprietary test development with a revenue-generating laboratory services business.
View full company profileTherapeutic Areas
Other Endometriosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Promarker™Endo | Proteomics International | Late‑stage validation |
| EV‑Endo | Cartherics | Preclinical |
| Endometriosis Program | Cyclana Bio | Discovery |
| Endometriosis Genetic Study | Juneau Biosciences | Discovery |
| Potential Diagnostic Development | Juneau Biosciences | Research |
| Endometriosis Discovery Program | Metri Bio | Discovery |
| Endometriosis Test Suite | Heranova Lifesciences | Pre-clinical |
| ENDO-205 | EndoCyclic Therapeutics | Phase 1 |
| Undisclosed Immunotherapy | Apheon Bioscience | Preclinical |
| FMC | FimmCyte | Pre-clinical |
| ABC-201 | Abcely | Preclinical |
| ERβ Modulator Program | Cadenza Bio | Preclinical |